ArticleOPEN ACCESS

STAT5 as a CML target: STATinib therapies?

Blood
DOI: 10.1182/blood-2011-01-332569
10Citations
Citations of this article
22Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In this issue of Blood,Nelson and colleagues1 and Warsch and colleagues2 report that signal transducers and activators of transcription 5 (STAT5) is an attractive target to circumvent tyrosine kinase inhibitor (TKI) resistance in chronic myeloid leukemia (CML).

Cite

CITATION STYLE

APA

Turhan, A. G. (2011, March 24). STAT5 as a CML target: STATinib therapies? Blood. American Society of Hematology. https://doi.org/10.1182/blood-2011-01-332569

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free